CNS targeting of some novel 4 thiazolidinone derivatives as SIRT3 activators for the treatment of Parkinsons disease

dc.contributor.guide	Gomathy, S
dc.coverage.spatial	Pharmacy
dc.creator.researcher	Sherin, Farhath
dc.date.accessioned	2023-10-05T09:19:33Z
dc.date.available	2023-10-05T09:19:33Z
dc.date.awarded	2023
dc.date.completed	2023
dc.date.registered	2019
dc.description.abstract	Available
dc.description.note	Summary 54-55p References 56-66p
dc.format.accompanyingmaterial	CD
dc.format.dimensions	3
dc.format.extent	1-103p
dc.identifier.uri	http://hdl.handle.net/10603/516075
dc.language	English
dc.publisher.institution	Colleges of Pharmacy
dc.publisher.place	Mysore
dc.publisher.university	JSS Academy of Higher Education and Research
dc.relation	134
dc.rights	university
dc.source.university	University
dc.subject.keyword	Clinical Pre Clinical and Health
dc.subject.keyword	Pharmacology and Pharmacy
dc.subject.keyword	Pharmacology and Toxicology
dc.title	CNS targeting of some novel 4 thiazolidinone derivatives as SIRT3 activators for the treatment of Parkinsons disease
dc.title.alternative
dc.type.degree	Ph.D.